PubRank

AAV2-GDNF for Advanced Parkinson s Disease

Clinical Trial ID NCT01621581

PubWeight™ 11.94‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01621581

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 2002 5.93
2 Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res 2000 1.45
3 Advances in non-dopaminergic treatments for Parkinson's disease. Front Neurosci 2014 0.93
4 Gene expression patterns for GDNF and its receptors in the human putamen affected by Parkinson's disease: a real-time PCR study. Mol Cell Endocrinol 2006 0.93
5 Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics 2014 0.92
6 Recombinant adenoassociated virus 2/5-mediated gene transfer is reduced in the aged rat midbrain. Neurobiol Aging 2014 0.83
7 SAFETY AND TOLERABILITY OF MRI-GUIDED INFUSION OF AAV2-hAADC INTO THE MID-BRAIN OF NON-HUMAN PRIMATE. Mol Ther Methods Clin Dev 2014 0.83
8 Gene-based therapies in Parkinson's disease. Neurotherapeutics 2014 0.83
9 Therapeutic approaches in Parkinson's disease and related disorders. J Neurochem 2016 0.78
10 Gene therapy for misfolding protein diseases of the central nervous system. Neurotherapeutics 2013 0.77
11 Widespread AAV1- and AAV2-mediated transgene expression in the nonhuman primate brain: implications for Huntington's disease. Mol Ther Methods Clin Dev 2016 0.77
12 A regulatable AAV vector mediating GDNF biological effects at clinically-approved sub-antimicrobial doxycycline doses. Mol Ther Methods Clin Dev 2016 0.77
13 There must be a way out of here: identifying a safe and efficient combination of promoter, transgene, and vector backbone for gene therapy of neurological disease. Mol Ther 2014 0.76
14 Neurotrophic factors: promising candidates in tissue regeneration. Neural Regen Res 2016 0.76
15 Recombinant adeno-associated virus vectors in the treatment of rare diseases. Expert Opin Orphan Drugs 2015 0.75
16 Neurotrophic factor therapy for Parkinson's disease: past, present and future. Neural Regen Res 2016 0.75
17 Growth factor therapy sequesters inflammation in affording neuroprotection in cerebrovascular diseases. Expert Rev Neurother 2016 0.75
18 Tet-On Systems For Doxycycline-inducible Gene Expression. Curr Gene Ther 2016 0.75
Next 100